Neutrophils activate plasmacytoid dendritic cells by releasing self-DNA–peptide complexes in systemic lupus erythematosus
…, G Chamilos, R Sebasigari, V Riccieri… - Science translational …, 2011 - science.org
Systemic lupus erythematosus (SLE) is a severe and incurable autoimmune disease
characterized by chronic activation of plasmacytoid dendritic cells (pDCs) and production of …
characterized by chronic activation of plasmacytoid dendritic cells (pDCs) and production of …
Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database
…, G Szucs, CA Von Mühlen, V Riccieri… - Annals of the …, 2010 - ard.bmj.com
Objectives To determine the causes and predictors of mortality in systemic sclerosis (SSc).
Methods Patients with SSc (n=5860) fulfilling the American College of Rheumatology criteria …
Methods Patients with SSc (n=5860) fulfilling the American College of Rheumatology criteria …
The antimicrobial peptide LL37 is a T-cell autoantigen in psoriasis
…, B Marinari, S Chon, L Vence, V Riccieri… - Nature …, 2014 - nature.com
Psoriasis is a common T-cell-mediated skin disease with 2–3% prevalence worldwide. Psoriasis
is considered to be an autoimmune disease, but the precise nature of the autoantigens …
is considered to be an autoimmune disease, but the precise nature of the autoantigens …
Mapping and predicting mortality from systemic sclerosis
…, N Damjanov, MJ Salvador, V Riccieri… - Annals of the …, 2017 - ard.bmj.com
Objectives To determine the causes of death and risk factors in systemic sclerosis (SSc).
Methods Between 2000 and 2011, we examined the death certificates of all French patients …
Methods Between 2000 and 2011, we examined the death certificates of all French patients …
Preliminary criteria for the very early diagnosis of systemic sclerosis: results of a Delphi Consensus Study from EULAR Scleroderma Trials and Research Group
J Avouac, J Fransen, UA Walker, V Riccieri… - Annals of the …, 2011 - ard.bmj.com
Objective To identify a core set of preliminary items considered as important for the very
early diagnosis of systemic sclerosis (SSc). Methods A list of items provided by European …
early diagnosis of systemic sclerosis (SSc). Methods A list of items provided by European …
[HTML][HTML] Standardisation of nailfold capillaroscopy for the assessment of patients with Raynaud's phenomenon and systemic sclerosis
…, S Paolino, C Pizzorni, M Radic, V Riccieri… - Autoimmunity …, 2020 - Elsevier
Capillaroscopy is a non-invasive and safe tool which allows the evaluation of the morphology
of the microcirculation. Since its recent incorporation in the 2013 American College of …
of the microcirculation. Since its recent incorporation in the 2013 American College of …
Prevalence and factors associated with left ventricular dysfunction in the EULAR Scleroderma Trial and Research group (EUSTAR) database of patients with systemic …
…, A Komócsi, D Farge, A Balbir, V Riccieri… - Annals of the …, 2010 - ard.bmj.com
Objectives: To measure the prevalence of, and factors associated with, left ventricular (LV)
dysfunction in systemic sclerosis (SSc). Methods: The EUSTAR database was first searched. …
dysfunction in systemic sclerosis (SSc). Methods: The EUSTAR database was first searched. …
Genome-Wide Scan Identifies TNIP1, PSORS1C1, and RHOB as Novel Risk Loci for Systemic Sclerosis
Systemic sclerosis (SSc) is an orphan, complex, inflammatory disease affecting the immune
system and connective tissue. SSc stands out as a severely incapacitating and life-…
system and connective tissue. SSc stands out as a severely incapacitating and life-…
“To be or not to be,” ten years after: evidence for mixed connective tissue disease as a distinct entity
…, CG Kiss, AK Tausche, S Cardarelli, V Riccieri… - Seminars in arthritis and …, 2012 - Elsevier
OBJECTIVES: To determine if mixed connective tissue disease (MCTD) can be considered
an independent clinical entity, to compare 3 different classification criteria for MCTD (…
an independent clinical entity, to compare 3 different classification criteria for MCTD (…
Outcomes of patients with systemic sclerosis-associated polyarthritis and myopathy treated with tocilizumab or abatacept: a EUSTAR observational study
…, F Bartoli, G Fiori, M Bokarewa, V Riccieri… - Annals of the …, 2013 - ard.bmj.com
Objective To evaluate the safety and effectiveness of tocilizumab and abatacept in systemic
sclerosis (SSc)-polyarthritis or SSc-myopathy. Methods 20 patients with SSc with refractory …
sclerosis (SSc)-polyarthritis or SSc-myopathy. Methods 20 patients with SSc with refractory …